Management of multiple sclerosis across managed care and fee-for-service systems

Neurology

Volumn 55, Issue 9, 2000, Pages 1341-1349

  Vickrey, B G ^a   Shatin, D ^f   Wolf, S M ^d   Myers, L W ^a   Belin, T R ^b   Hanson, R A ^e   Shapiro, M F ^b   Beckstrand, M ^a   Edmonds, Z V ^a   Delrahim, S ^c   Ellison, G W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KAISER PERMANENTE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNITEDHEALTH GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; BLADDER FUNCTION; CONTROLLED STUDY; DISEASE SEVERITY; FATIGUE; FEMALE; HEALTH CARE NEED; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MOBILIZATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; QUESTIONNAIRE; SYMPTOM; UNITED STATES;

EID: 0034649376     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.9.1341     Document Type: Article

References (34)

1. Evolution, growth, and status of managed care in the United States
2. Structure and performance of health maintenance organizations: A review
3. Impact of managed care on quality of healthcare: Theory and evidence
4. Comparing fee-for-service vs. managed care: Out-of-pocket expenses for low-income families with children with special needs
5. The duration of ambulatory visits to physicians
6. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
7. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group
8. 1(b) is effective in relapsing-remitting multiple sclerosis I Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group
9. 1(b) in the treatment of multiple sclerosis final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group
10. Interferons in the treatment of multiple sclerosis: Do they prevent the progression of the disease?
11. Interferons should be used to treat most patients with MS
12. Interferons in the treatment of multiple sclerosis
13. Multiple sclerosis care: An integrated disease-management model
14. General neurologist and subspecialist care for multiple sclerosis: Patients' perceptions
15. The Medical Outcomes Study. An application of methods for monitoring the results of medical care
16. Variations in the care of HIV-Infected adults in the United States: Results from the HIV Cost and Services Utilization Study
17. Ability to obtain health care: Recent estimates from the Robert Wood Johnson Foundation National Access to Care Survey
18. Eye on patients: Excerpts from a report on patients' concerns and experiences about the health care system American Hospital Associationn and the Picker Institute
19. A proposal for a uniform minimal record of disability in multiple sclerosis
20. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
21. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses
22. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
23. Managed care plan performance since 1980: A literature analysis
24. Variations in resource utilization among medical specialties and systems of care. Results from the Medical Outcomes Study
25. Comparison of care for persons with multiple sclerosis in fee-for-service and managed care systems
26. Insurance coverage, physician recommendations, and access to emerging treatments: Growth hormone therapy for childhood short stature
27. Health promotion in primary care: Physician-patient communication and decision making about prescription medications
28. What people with epilepsy want from a hospital clinic
29. Patients' experiences of and satisfaction with care for their epilepsy
30. The increasing importance of patient surveys: Now that sound methods exist, patient surveys can facilitate improvement
31. Health care quality: Incorporating consumer perspectives
32. The patient's role in health care and quality assessment